ライフサイエンスコーパス: serum bilirubin

1 efore, it is an important candidate gene for serum bilirubin.

2 d to an increase in the free fraction of his serum bilirubin.

3 jaundice due to an increase in unconjugated serum bilirubin.

4 ound most portal veins, with no elevation of serum bilirubin.

5 ral nutrition requirements, cause of GF, and serum bilirubin.

6 imated glomerular filtration rate, and total serum bilirubin.

7 n, estimated glomerular filtration rate, and serum bilirubin.

8 ociated with a greater than 25% reduction in serum bilirubin.

9 sk of death included higher than 115 mumol/L serum bilirubin 2-5 days after biliary stenting (HR 3.27

10 type I biliary atresia with jaundice (total serum bilirubin, 22.2 mg/dL), hypoalbuminemia (serum alb

11 ] vs. 1.9 mg/dL [0.8-3.2 mg/dL]; p < 0.001), serum bilirubin (5.9 mg/dL [3.7-9.5 mg/dL] vs. 1.1 mg/dL

12 ality rises steeply with small increments of serum bilirubin above normal.

13 P = 0.015] among those who normalized their serum bilirubin after PE.

14 dose of the virus on day 98 markedly reduced serum bilirubin again.

15 of liver dysfunction such as high levels of serum bilirubin, alkaline phosphatase, alanine transamin

16 Univariate analysis identified serum bilirubin, alkaline phosphatase, and urinary bilir

17 5D-itch correlated positively with serum bilirubin, ALP, ALT and AST; and negatively with C

18 Additionally, increased serum bilirubin and alanine aminotransferase levels were

19 were ambulatory with mostly normal levels of serum bilirubin and albumin concentrations.

20 tic cholestasis as seen by decreases in both serum bilirubin and alkaline phosphatase levels in TG mi

21 but not Ad5LacZ, as demonstrated by elevated serum bilirubin and ammonia levels.

22 es population and hour-based norms for total serum bilirubin and assessment of risk factors.

23 R surgery, the following were determined: 1) serum bilirubin and bile acid levels; 2) serum levels of

24 After reperfusion: 1) serum bilirubin and bile acids increased; 2) levels of a

25 An inverse association between serum bilirubin and coronary heart disease has been repo

26 e disease) is calculated on the basis of the serum bilirubin and creatinine concentrations and the in

27 multivariate modeling, elevated pretreatment serum bilirubin and creatinine levels as well as the pre

28 r End-Stage Liver Disease (MELD) consists of serum bilirubin and creatinine levels, International Nor

29 s who received itraconazole developed higher serum bilirubin and creatinine values in the first 20 da

30 Serum bilirubin and other hepatic variables gradually im

31 Postoperative serum bilirubin and prothrombin time-international norma

32 s the length of hospital stay, postoperative serum bilirubin and PT-INR, as well as infectious and ov

33 expression post-CPB was associated with low serum bilirubin and reduced preoperative expression of b

34 primary nonfunction identified preoperative serum bilirubin and serum creatinine as significant pred

35 ing toxicities were related to elevations in serum bilirubin and serum creatinine levels.

36 diabetes, hepatitis C status, serum albumin, serum bilirubin and serum creatinine.

37 re correlated with a progressive increase in serum bilirubin and the development of a predominantly l

38 inophen concentration, prothrombin time, and serum bilirubin and transaminase concentrations.

39 At 24 hours after collar implantation, serum bilirubin and vascular, liver, and spleen HO-1 mes

40 17.1 mumol/L (>/=1 mg/dL), normal conjugated serum bilirubin, and no evidence of hepatitis, cholestas

41 cirrhosis related HCC patients pre-procedure serum bilirubin, ascites, tumour size and female gender

42 In conclusion, the value of total serum bilirubin at a particular point in time after tran

43 core and HE at admission and the increase in serum bilirubin at day 4 were independent predictors of

44 increased from 53 to 56 years and the median serum bilirubin at transplantation fell from 270 micromo

45 lestasis after BDL was confirmed by baseline serum bilirubin (BDL = 7.34 +/- 0.72 mg/dl, mean +/- SEM

46 splant survival: high serum creatinine, high serum bilirubin, biliary tree malignancy, previous upper

47 , intraoperative hypotension and predonation serum bilirubin, but did not decline with the increased

48 s negatively associated with an elevation of serum bilirubin, but how bilirubin worsens outcomes rema

49 heparin was defined as a reduction in total serum bilirubin by 50% within 10 days of starting treatm

50 ection of Ad-BUGT1, but not Ad-LacZ, reduced serum bilirubin by 70-76% of the levels in untreated pup

51 after infection, but showed no reduction of serum bilirubin by reinjection of the virus on that day.

52 iota is essential to human health, as excess serum bilirubin can cause jaundice and even neurological

53 Jaundice was defined as a serum bilirubin concentration > or = 3 mg/dL.

54 The optimal model included the total serum bilirubin concentration, oral intake, need for tre

55 encephalopathy; sustained quadrupling of the serum bilirubin concentration; marked worsening of fatig

56 The observed inverse correlation between serum bilirubin concentrations and a history of nonderma

57 There is an inverse relationship between serum bilirubin concentrations and risk of coronary arte

58 gical malignancy exhibit significantly lower serum bilirubin concentrations compared with those who d

59 ubin-UGT-deficient jaundiced Gunn rats, mean serum bilirubin concentrations decreased by 40%, 60% and

60 zygote UGT1A1*28 allele carriers with higher serum bilirubin concentrations exhibit a strong associat

61 art of conditioning therapy for unconjugated serum bilirubin concentrations of at least 17.1 mumol/L

62 mic effect was observed in group A, in which serum bilirubin concentrations were reduced to 1.7+/-0.4

63 The primary endpoint was the change of serum bilirubin, creatinine and serum BUN levels before

64 , a new model, based on recipient age, total serum bilirubin, creatinine, and interval to re-OLT, was

65 ng of the international normalized ratio and serum bilirubin, creatinine, and sodium, has been used t

66 D staging was defined by the extent of rash, serum bilirubin, diarrhea, and confirmatory histology.

67 nts treated with weekly irinotecan, baseline serum bilirubin does not reliably predict overall irinot

68 Mean total serum bilirubin fell from 9.14 +/- 0.01 to a nadir of 1.

69 up to 72 hours of age or a decrease in total serum bilirubin for infants older than 72 hours of age w

70 Serum bilirubin, gamma-glutamyltranspeptidase, and chole

71 mm Hg best predicted PLF defined by peak of serum bilirubin greater than 120 mumol/L and 90-day mort

72 efinitions of PLF: "50-50" criteria, peak of serum bilirubin greater than 120 mumol/L, and grade C PL

73 for iDILI were defined as serum ALT > 5x or serum bilirubin > 1.5x upper limit of normal in the sett

74 umption, elevated AST and/or ALT (<300 U/L), serum bilirubin >34 mumol/L, and elevated INR.

75 opathy, variceal bleeding, prothrombin <45%, serum bilirubin >45 mumol/L, albumin <28 g/L, and/or cre

76 -50 criteria" (ie, prothrombin time <50% and serum bilirubin >50 micromol/L on postoperative day 5) a

77 ic regression analysis, SSM-VCTE >40 kPa and serum bilirubin >=1 mg/dL were associated with HRV.

78 Increased serum bilirubin has been shown to be a negative predicti

79 Serum bilirubin higher than 115 mumol/L 2-5 days after t

80 mparison), even after excluding those with a serum bilirubin higher than 2.0 mg/dL.

81 vanced disease and demonstrated decreases in serum bilirubin, improvement in coagulopathy, and decrea

82 is mostly benign, excessively high levels of serum bilirubin in a small percentage of newborns can ca

83 event was a moderate transient elevation in serum bilirubin in one participant.

84 The sensitivity of Total serum bilirubin in predicting complicated appendicitis w

85 Mean serum bilirubin in these nine patients was 8.7 mg/dl bef

86 Similarly, serum bilirubin increased by a mean of 0.34 mg/dl in ind

87 After 2 mo serum bilirubin increased gradually.

88 ) status, nutritional status, serum albumin, serum bilirubin, international normalized ratio, and the

89 for End-Stage Liver Disease variations, age-serum bilirubin-international normalized ratio-serum Cre

90 Serum bilirubin is a potent endogenous antioxidant and h

91 Serum bilirubin is an endogenous antioxidant that is rou

92 In particular, each 1-mg/dL increase in serum bilirubin is associated with a markedly decreased

93 Variation in serum bilirubin is associated with altered cardiovascula

94 In biliary atresia, serum bilirubin is commonly used to predict outcomes aft

95 antation, GVHD prophylaxis, gender mismatch, serum bilirubin, Karnofsky score, and platelet count.

96 tes, variceal bleeding, or encephalopathy; a serum bilirubin less than 3 mg/dL; serum albumin 3 g/dL

97 native liver at 24 months of age with total serum bilirubin less than 6 mg/dL (n = 54).

98 therapy, significantly reduced the mean peak serum bilirubin level (7.0 vs. 9.8 mg per deciliter [120

99 Serum bilirubin level decreased significantly in the FPS

100 This is to conclude that Serum bilirubin level estimation, which is a simple, che

101 logic disorder versus solid tumor (P = .06), serum bilirubin level greater than 1.1 mg/dL (P = .08),

102 Serum bilirubin level measured before a statin prescript

103 nderwent a successful KP, defined as a total serum bilirubin level of <=25 mumol/L within 6 months af

104 fety and efficacy; efficacy was defined as a serum bilirubin level of 300 mumol per liter or lower me

105 The median serum bilirubin level of the patients was 21.8 mg/dl, 85

106 The median peak serum bilirubin level through day 20 was 2.6 mg/dL (rang

107 L-1 patients had transient elevations in the serum bilirubin level to > or = 4 mg/dL.

108 The serum bilirubin level was reduced from 7.1 +/- 0.75 mg/d

109 In noncirrhotic patients, the serum bilirubin level was significantly (p < 0.05) reduc

110 -/-) mice develop significantly higher total serum bilirubin levels (23.2 +/- 2.3 versus 14.9 +/- 2.1

111 factors (6% vs. 70%; P < .001), higher peak serum bilirubin levels (45% vs. 5% with peak levels > 15

112 575 participants with 2,532 diabetes cases), serum bilirubin levels (total, direct and indirect) incr

113 Serum bilirubin levels also fell from a median of 385 to

114 report an association between neonatal total serum bilirubin levels and childhood asthma.

115 Early postoperative testing of serum bilirubin levels and hepatobiliary scintigraphy ar

116 t support the protective association between serum bilirubin levels and incident T2D in the middle-ag

117 ty of liver disease as assessed via elevated serum bilirubin levels and low levels of serum albumin a

118 autoantibodies with outcomes were performed (serum bilirubin levels and need for liver transplant in

119 ssociated with overall mortality, and higher serum bilirubin levels and stage 4 fibrosis were associa

120 ctional and prospective associations between serum bilirubin levels and T2D risk in the Dongfeng-Tong

121 Serum bilirubin levels are influenced by many factors, b

122 Serum bilirubin levels are significantly higher in men (

123 on of human BUGT1 (hBUGT1) with reduction of serum bilirubin levels by 70%.

124 ntify genetic contributors to variability in serum bilirubin levels by combining results from three g

125 for UGT1A1*28 (genotype 7/7) have increased serum bilirubin levels compared with carriers of the 6 a

126 ubin glucuronides were excreted in bile, and serum bilirubin levels declined by 25-35% in 2-4 weeks a

127 Serum bilirubin levels declined by 30% +/- 4% in 2 weeks

128 Serum bilirubin levels decreased from 7.2 to 1.8 mg/dl w

129 nthetic function or with lower pretransplant serum bilirubin levels fared as well as younger patients

130 glucuronides in bile and a reduction of mean serum bilirubin levels from 7.0 mg/dl to 1.9-2.7 mg/dl w

131 ne expression was shown by reduction of mean serum bilirubin levels from 7.0 mg/dL to 2.3 mg/dL in 14

132 n in the gene encoding the UGT1*1 enzyme and serum bilirubin levels in a Scottish population.

133 velopmental risks associated with high total serum bilirubin levels in newborns are not well defined.

134 By week 16, serum bilirubin levels in patients who received the lowe

135 Phenobarbital treatment "normalized" serum bilirubin levels in recipients of orthotopic Wista

136 determine the demographics and correlates of serum bilirubin levels in the general population.

137 ar was superior for patients who had maximal serum bilirubin levels in the normal (78%) or minimally

138 that UGT1A1 may be a major gene controlling serum bilirubin levels in the population.

139 phototherapy or exchange transfusion, total serum bilirubin levels in the range included in this stu

140 Serum bilirubin levels increased slightly with each drug

141 In Ad-E3-hBUGT-injected rats, serum bilirubin levels increased to 4.5 mg/dl by 84 days

142 In contrast, rats receiving Ad-hBUGT had serum bilirubin levels of 7 mg/dl on day 84 after infect

143 e identified 140 infants with neonatal total serum bilirubin levels of at least 25 mg per deciliter (

144 tive than the wild-type six repeats, and the serum bilirubin levels of persons homozygous or even het

145 trong replication for a genetic influence on serum bilirubin levels of the UGT1A1 locus (P < 5 x 10(-

146 tabase (the Health Improvement Network) with serum bilirubin levels recorded but no evidence of hepat

147 aused human BUGT1 expression again, reducing serum bilirubin levels to those observed after the first

148 In conclusion, serum bilirubin levels vary significantly with gender, r

149 th biliary atresia, a younger age and higher serum bilirubin levels were linked to increased HRV risk

150 vels were elevated in some LEC rats, whereas serum bilirubin levels were normal.

151 ing antibodies and a CTL response, and their serum bilirubin levels were not reduced following subseq

152 was detectable in liver for 2 days only, and serum bilirubin levels were not reduced.

153 In control rats serum bilirubin levels were reduced for only 4 wk, and v

154 Serum bilirubin levels were significantly decreased by 3

155 /- mice than in wild-type CBDL mice, whereas serum bilirubin levels were the same, suggesting that Mr

156 We examined the association of serum bilirubin levels with nonrelapse mortality by day

157 approximately 1.0% of the variation in total serum bilirubin levels, respectively.

158 s but exhibited higher hepatic bile acid and serum bilirubin levels, suggesting defects in bile expor

159 in the UDPGT family directly associated with serum bilirubin levels, which is in turn implicated with

160 e, white blood cell, and platelet counts and serum bilirubin levels.

161 ndrome (veno-occlusive disease) and by total serum bilirubin levels.

162 ion and predisposes the infant to high total serum bilirubin levels.

163 ion period, and associated with reduction of serum bilirubin levels.

164 unal transplants from Wistar rats normalizes serum bilirubin levels.

165 al Wistar rats lowered but did not normalize serum bilirubin levels.

166 ilirubin glucuronides and a 70% reduction of serum bilirubin levels.

167 n of UGT1A1 in the small intestine to reduce serum bilirubin levels.

168 ile was done in all the patients with normal serum bilirubin levels.

169 ic toxicity, as well as baseline and maximal serum bilirubin levels.

170 phenobarbital has been used for reducing the serum bilirubin load.

171 ancer compared with those with CCA had lower serum bilirubin, lower carbohydrate antigen 19-9 (CA 19-

172 bove 50%), and have adequate organ function (serum bilirubin </=3.0 mg/dL and serum creatinine </=3.0

173 n peak, 510 U/L; range, 286 to 770 U/L), and serum bilirubin (mean peak, 160.7 micromol/L [9.4 mg/dL]

174 Among these, only serum bilirubin nearly approached significance ( p = 0.0

175 r transplantation, alanine aminotransferase, serum bilirubin, necrosis, and apoptosis all increased.

176 associated with poor prognosis were baseline serum bilirubin, no reversibility of type-1 HRS, lack of

177 bility of type-1 HRS were age, high baseline serum bilirubin, nosocomial infection, and reduction in

178 Transient elevations in serum bilirubin occurred in all treatment groups.

179 /dl, 95% CI 1.1 to 1.4), pretransplant total serum bilirubin (odds ratio 1.4 for each 10-mg/dl increa

180 ortic balloon counterpulsation, preoperative serum bilirubin of >1.0 mg/dL, blood transfusion require

181 l steroid treatment was defined as a drop in serum bilirubin of <25% within 7 days or death within 6

182 h was defined as a rate of increase in total serum bilirubin of less than 0.2 mg per deciliter per ho

183 tients were aged 65 years or younger and had serum bilirubin of less than 1.5 mg/dL, creatinine clear

184 ons (grade >/= 3b) after stage 1 (OR = 3.4), serum bilirubin (OR = 4.4), serum creatinine (OR = 5.4),

185 ), ascites (p = 0.030, OR = 1.212), elevated serum bilirubin (p = 0.007, OR = 4.357) and large tumour

186 r >5 cm (p = 0.049, OR = 2.410) and elevated serum bilirubin (p = 0.036, OR = 1.517) predicted AHD.

187 On univariate analysis elevated serum bilirubin (p = 0.046) and low serum albumin (p = 0

188 preoperative serum creatinine (P=0.001) and serum bilirubin (P=0.02) levels were associated with a h

189 Total serum bilirubin, percent weight gain, and serum creatini

190 Mean total serum bilirubin plummeted from 8.41 +/- 0.20 to 0.76 +/-

191 ation of serum albumin, and concentration of serum bilirubin predict the risk of complications and de

192 y of liver disease, grade of encephalopathy, serum bilirubin, prothrombin time, creatinine, serum pho

193 0.16), while FEV1% was positively related to serum bilirubin (r = 0.15).

194 , serum creatinine (relative risk, 3.8), and serum bilirubin (relative risk, 3.7) were found to be in

195 ch is evident from a significant decrease in serum bilirubin, reticulocyte counts, and serum erythrop

196 station at 12 facilities that used universal serum bilirubin screening before (January 1, 2010, throu

197 s of our nontransplanted patients identified serum bilirubin, serum albumin, blood urea, ascites, and

198 Data on serum bilirubin, serum IgG4 level, stent type, and respo

199 ter birth that lead to the rapid increase in serum bilirubin, the events that control delayed express

200 s, encephalopathy, or varices; a doubling of serum bilirubin to 2.5 mg/dL or greater; a fall in serum

201 onstrated significant evidence of linkage of serum bilirubin to chromosome 2q, with a LOD score of 3.

202 at definition of CS was applied (e.g., total serum bilirubin (TSB) < 2 mg/dl: 66.1% vs. 27.8%, p = <

203 ) mice, which exhibit severe levels of total serum bilirubin (TSB) because of a developmental delay i

204 hildren exposed to excessive levels of total serum bilirubin (TSB) during the neonatal period.

205 usion is recommended for newborns with total serum bilirubin (TSB) levels thought to place them at ri

206 Total serum bilirubin (TSB) levels were examined at 48 hours p

207 mentally delayed resulting in elevated total serum bilirubin (TSB) levels.

208 tal jaundice are based on age-specific total serum bilirubin (TSB) levels.

209 earson correlation, and agreement with total serum bilirubin (TSB).

210 Total serum bilirubin values up to day +100, death, or relapse

211 f intestinal UGT1A1 and a reduction in total serum bilirubin values.

212 ients treated with twice-daily HDAC when the serum bilirubin was > or = 2.0 mg/dL compared with twice

213 a median follow-up of 15.8 months, baseline serum bilirubin was not predictive of 1-year survival (4

214 A clinically significant reduction in serum bilirubin was observed with a dose as low as 6 x 1

215 Serum bilirubin was of no prognostic value in ALF, and N

216 With histidine containing FPL, serum bilirubin was reduced by 40% +/- 5%, and bilirubin

217 ng negative association between CVD-risk and serum bilirubin we further explored potential associatio

218 trolox equivalent antioxidant capacity, and serum bilirubin, which may protect against lipid peroxid

219 e after Kasai portoenterostomy and will have serum bilirubin within the normal range within 6 months.